INO Inovio Pharmaceuticals Inc

Price (delayed)

$8.59

Market cap

$1.8B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.09

Enterprise value

$1.75B

Highlights
Inovio Pharmaceuticals's debt has shrunk by 66% YoY and by 13% QoQ
INO's quick ratio has surged by 52% year-on-year and by 23% since the previous quarter
INO's revenue has soared by 147% year-on-year but it is down by 13% since the previous quarter
The gross profit has surged by 147% year-on-year but it has declined by 13% since the previous quarter
INO's net income has dropped by 53% year-on-year and by 13% since the previous quarter

Key stats

What are the main financial stats of INO
Market
Shares outstanding
209.4M
Market cap
$1.8B
Enterprise value
$1.75B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.07
Price to sales (P/S)
269.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
270.95
Earnings
Revenue
$6.46M
EBIT
-$181.86M
EBITDA
-$177.37M
Free cash flow
-$206.98M
Per share
EPS
-$1.09
Free cash flow per share
-$1.02
Book value per share
$2.8
Revenue per share
$0.03
TBVPS
$3.17
Balance sheet
Total assets
$654.86M
Total liabilities
$73.26M
Debt
$33.9M
Equity
$581.61M
Working capital
$546.9M
Liquidity
Debt to equity
0.06
Current ratio
14.17
Quick ratio
12.73
Net debt/EBITDA
0.28
Margins
EBITDA margin
-2,747.8%
Gross margin
100%
Net margin
-2,916.7%
Operating margin
-2,345.5%
Efficiency
Return on assets
-36.3%
Return on equity
-48.5%
Return on invested capital
-52.8%
Return on capital employed
-29.7%
Return on sales
-2,817.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INO stock price

How has the Inovio Pharmaceuticals stock price performed over time
Intraday
2.26%
1 week
3.74%
1 month
-4.77%
1 year
-55.81%
YTD
-2.94%
QTD
-7.34%

Financial performance

How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$6.46M
Gross profit
$6.46M
Operating income
-$151.4M
Net income
-$188.27M
Gross margin
100%
Net margin
-2,916.7%
INO's revenue has soared by 147% year-on-year but it is down by 13% since the previous quarter
The gross profit has surged by 147% year-on-year but it has declined by 13% since the previous quarter
INO's net income has dropped by 53% year-on-year and by 13% since the previous quarter
The company's operating margin rose by 43% YoY but it fell by 40% QoQ

Growth

What is Inovio Pharmaceuticals's growth rate over time

Valuation

What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.07
P/S
269.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
270.95
INO's EPS is up by 7% year-on-year
The stock's price to book (P/B) is 70% less than its 5-year quarterly average of 10.2 and 66% less than its last 4 quarters average of 8.9
The equity has grown by 26% from the previous quarter
INO's revenue has soared by 147% year-on-year but it is down by 13% since the previous quarter
The P/S is 63% lower than the last 4 quarters average of 729.3 but 44% higher than the 5-year quarterly average of 187.5

Efficiency

How efficient is Inovio Pharmaceuticals business performance
INO's ROE has soared by 73% YoY and by 16% from the previous quarter
INO's return on assets is up by 41% year-on-year and by 4% since the previous quarter
INO's return on sales is up by 35% year-on-year but it is down by 32% since the previous quarter
The company's return on invested capital rose by 11% QoQ and by 7% YoY

Dividends

What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INO.

Financial health

How did Inovio Pharmaceuticals financials performed over time
The total assets has soared by 93% year-on-year and by 21% since the previous quarter
INO's current ratio has soared by 66% YoY and by 25% QoQ
Inovio Pharmaceuticals's debt is 94% lower than its equity
The debt to equity has plunged by 89% YoY and by 25% from the previous quarter
Inovio Pharmaceuticals's debt has shrunk by 66% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.